AAA
UTHR icon

Affinity Asset Advisors’s United Therapeutics UTHR Stock Holding History

Affinity Asset Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,000
Closed -$2.1M – 122
2025
Q3 		$2.1M Buy
+5,000
New +$1.68M 0.18% 74
2021
Q4 		– Sell
-10,000
Closed -$1.85M – 73
2021
Q3 		$1.85M Buy
+10,000
New +$1.97M 0.47% 43

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $49B AUM 17.78% 1-Year Est. Return

Affinity Asset Advisors's UTHR Position: Q4 2025 in Review

Affinity Asset Advisors sold out of United Therapeutics (UTHR) in Q4 2025, closing a stake of 5,000 shares — an estimated $2.1M sold.

Affinity Asset Advisors first reported a position in UTHR in Q3 2021 and held it in 2 quarters. The position peaked at $2.1M in Q3 2025. 837 funds tracked by Wall St. Rank hold UTHR as of Q4 2025.

  • Affinity Asset Advisors reported no remaining United Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Affinity Asset Advisors sold 5,000 United Therapeutics shares in Q4 2025, an estimated $2.1M.
  • Affinity Asset Advisors first reported a position in United Therapeutics in Q3 2021 and held it in 2 quarters.
  • Affinity Asset Advisors's United Therapeutics position peaked at $2.1M in Q3 2025.
  • 837 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2025.

Based on Affinity Asset Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.